



مركز الكويت لمكافحة السرطان
Kuwait Cancer Control Center

CERitinib (Zykadia®)



Ministry of Health

Name:

File #:

Ht (cm):

Nationality:

Civil ID:

Wt (Kg):

Gender/Age:

DOB:

BSA (m²):

Indication(s): Advanced stage ALK positive lung adenocarcinoma:

First-line therapy.

Subsequent-line therapy after failure or intolerance to Crizotinib.

Central line: Available NA

Allergies: NKA Yes, specify; _____

Standard Protocol:

DRUG	DOSE	ADMINISTRATION
CERitinib	750 mg PO once daily	To be given on an empty stomach at least 2 hrs before or 2 hrs after a meal. If a dose is missed, take the missed dose unless the next dose is due within 12 hours. If vomiting occurs, do not administer an additional dose and continue with the next scheduled dose.
To be given continuously until disease progression or intolerable toxicity.		

Special instructions:

- Avoid grapefruit and grapefruit juice.
- Avoid Acid-suppressive drugs such as proton-pump inhibitors, H2 antagonists, and antacids.
- Avoid drugs that prolong the QT interval.
- Avoid concomitant use with strong CYP3A4 inducers (Anticonvulsants) and inhibitors.

Treatment Description:

Cycle	Date	CERitinib	Physician	Consultant
C# __				
C# __				
C# __				
C# __				
C# __				
C# __				

Important Notes:

Reported grade 3/4 toxicities: None Hematological Non-Hematological

If yes; Did it indicate hospitalization? Yes No

Did it indicate chemo-delay for ≥ 7 days? Yes No

Did it indicate dose reduction? Yes No

Did it indicate G-CSF support? Yes No